Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProQR Therapeutics NV PRQR

Healthcare Biotechnology
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is... see more

Recent & Breaking News (NDAQ:PRQR)

ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer

GlobeNewswire October 5, 2020

ProQR Announces Virtual Presentations at Scientific Conferences

GlobeNewswire September 24, 2020

ProQR to Participate in Upcoming Investor Conferences

GlobeNewswire September 3, 2020

ProQR Announces Second Quarter 2020 Operating and Financial Results

GlobeNewswire August 6, 2020

ProQR Strengthens Scientific Advisory Board with Leaders in Inherited Retinal Disease and RNA Therapy

GlobeNewswire July 21, 2020

ProQR Announces $30 Million Strategic Convertible Debt Financing Agreement with Pontifax Ventures

GlobeNewswire July 14, 2020

ProQR Announces Expert Perspectives Call on LCA10 and Sepofarsen

GlobeNewswire July 13, 2020

ProQR Announces Expert Perspectives Conference Call Series

GlobeNewswire June 12, 2020

ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Data Through the Association for Research in Vision and Ophthalmology (ARVO)

GlobeNewswire June 8, 2020

ProQR Announces Annual Meeting of Shareholders

GlobeNewswire May 25, 2020

ProQR Announces First Quarter 2020 Operating and Financial Results

GlobeNewswire May 7, 2020

ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update

GlobeNewswire March 31, 2020

ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome

GlobeNewswire March 25, 2020

ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update

GlobeNewswire February 26, 2020

ProQR to Present at Cowen and Company 40th Annual Health Care Conference

GlobeNewswire February 24, 2020

ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases

GlobeNewswire February 6, 2020

ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a

GlobeNewswire January 30, 2020

ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa

GlobeNewswire December 11, 2019

ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa

GlobeNewswire November 21, 2019

ProQR to Present at Upcoming Scientific Conferences

GlobeNewswire November 18, 2019